Modality
Bispecific Ab
MOA
PD-1i
Target
FLT3
Pathway
JAK/STAT
ASNASH
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
Apr 2021
→ Aug 2030
Phase 1Current
NCT07825488
1,495 pts·NASH
2024-06→2030-08·Not yet recruiting
NCT05822232
884 pts·NASH
2021-04→TBD·Not yet recruiting
2,379 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-164.4y awayPh2 Data· NASH
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2030-08-16 · 4.4y away
NASH
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07825488 | Phase 1/2 | NASH | Not yet recr... | 1495 | PFS |
| NCT05822232 | Phase 1/2 | NASH | Not yet recr... | 884 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Motasacituzumab | Olema | NDA/BLA | FLT3 |